Digital Cognitive Health Company, Savonix, Unveils Japanese Website to Better Serve Clients and Expand Outreach in Japan

New Website Bridges the Language Gap and Opens Up New Partnership Opportunities in Cognitive Health Testing

SAN FRANCISCO–(BUSINESS WIRE)–#alzheimersSavonix, a global leader in digital cognitive health testing, is proud to announce the launch of its Japanese website – visitors are invited to explore at Savonix.jp.

The website explains the science behind Savonix’s brain health platform. It highlights ways the company can provide cognitive health and data insights to support people and companies in Japan to monitor brain health, understand risk factors for developing dementia and take steps to reduce the risk of getting dementia.

“I’m excited that the Savonix website is now available in Japan. Japan faces the world’s highest rate of dementia in a super aging society and we are thrilled to help the people of Japan with resources to better understand dementia and to monitor their brain health to reduce risk,” said Dr. Mylea Charvat, Founder, and CEO of Savonix. “The website also provides another avenue for us to stress the importance of taking cognitive assessments regularly and living a healthy lifestyle to prevent dementia.”

More than 4.6 million people in Japan suffer from some form of dementia, with the total expected to soar to about 7.3 million people by 2025. These numbers underscore the importance of cognitive testing for early detection of impairment. Savonix has always understood that importance – its flagship product, Savonix Mobile available in the app store provides cognitive tests and lifestyle risk assessments for dementia that can be taken on any mobile device and is available in Japan through our partnerships with Fujitsu Connected Technologies Limited and Mitani Sangyo companies.Co, Ltd.

Savonix is no newcomer in the Japanese market – it has partnered with Fujitsu Connected Technologies Limited and Mitani Sangyo companies.Co, Ltd to deliver accessible and accurate cognitive testing to users in the country.

For more information on Savonix, visit savonix.jp.

About Savonix

A global leader in cognitive health, Savonix delivers the only neuropsychology platform in the market. Savonix provides digital cognitive health solutions and empowers healthcare providers, payers, and researchers to evaluate and leverage results to improve health and treatment outcomes. Developed by clinical neuropsychologists and digital health technology experts, the Savonix Cognitive Assessment is an accurate, accessible, and affordable tool for downloading on all mobile devices.

Contacts

Savonix

Reynald Hiole

+1.415.919.7421

rhiole@savonix.com

Staff

Recent Posts

President Trump’s Cannabis Decision Is Coming – And Why MMJ International Holdings Wins Either Way

12 Month Timeline - How Cannabis Rescheduling Actually Takes EffectAnnouncementPresident signals intent or issues executive…

17 hours ago

Accelerating Patient Recruitment and Research Excellence: TrialWire® Supports Endpoints Clinical Trials Day NYC 2025

NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- TrialWire®, the industry’s fastest, intelligent patient recruitment…

22 hours ago

Genesis Healthcare Remains Committed to Securing Longterm Stability

The skilled nursing, assisted and senior living provider reiterates dedication to a financial restructuring process…

22 hours ago

Extendicare Announces December 2025 Dividend of C$0.042 per Share

MARKHAM, Ontario, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX:…

22 hours ago

Teva to Host Conference Call to Discuss Fourth Quarter 2025 Financial Results at 8 a.m. ET on January 28, 2026

TEL AVIV, Israel, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and…

22 hours ago